LRRC16B Activators
LRRC16B activators represent a specialized category of chemical agents designed to enhance the functional activity of the LRRC16B protein, which is implicated in various cellular processes, including cytoskeletal rearrangements and cell morphology regulation. These activators are developed through a meticulous process that begins with the identification of the structural and functional nuances of the LRRC16B protein. This understanding facilitates the design and synthesis of molecules that can bind to LRRC16B, promoting its activation rather than inhibiting its function. The activation of LRRC16B by these chemicals can influence cellular behavior in specific ways, making these activators valuable tools for probing the biological roles of LRRC16B and for investigating its potential as a target in conditions where its enhanced activity may be beneficial.
The development of LRRC16B activators involves several key steps, including computational modeling to predict potential binding sites and conformations, high-throughput screening to identify compounds with activating potential, and detailed biochemical and biophysical analyses to characterize the interaction between the activator and the LRRC16B protein. This is followed by structure-activity relationship (SAR) studies to optimize the activator's efficacy and specificity. Once promising activators are identified, their biological activity is validated through a series of in vitro and in vivo experiments designed to elucidate their effects on LRRC16B-mediated pathways and cellular outcomes. This comprehensive approach ensures that LRRC16B activators are highly selective and effective in modulating the protein's activity, providing insights into the physiological and pathological roles of LRRC16B.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels, which can activate PKA. PKA may then phosphorylate LRRC16B or associated regulatory proteins, enhancing LRRC16B's functional activity. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases, which increases cAMP by preventing its degradation, potentially enhancing PKA activity and subsequently LRRC16B activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate (S1P) engages S1P receptors, activating G protein-coupled receptor signaling that can lead to downstream effects on proteins such as LRRC16B through cytoskeletal rearrangements. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a diacylglycerol analog that activates PKC, which can influence the activity of proteins like LRRC16B by modulating the actin cytoskeleton and related signaling pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a kinase inhibitor with the potential to reduce competitive signaling pathways, possibly enhancing signaling pathways that positively regulate LRRC16B. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
PI3K inhibitor LY294002 could enhance the activity of LRRC16B by altering the PI3K/AKT pathway, which is involved in a variety of cellular processes including those related to the cytoskeleton and protein-protein interactions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that may enhance LRRC16B activity by similar mechanisms as LY294002, affecting downstream signaling that intersects with LRRC16B's functional pathways. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that could potentially enhance LRRC16B activity by shifting signaling away from p38 MAPK-mediated pathways, which might otherwise negatively regulate LRRC16B. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
Calcium ionophore A23187 increases intracellular calcium levels, which could activate calcium-dependent signaling pathways that enhance LRRC16B activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor leading to increased cytosolic calcium, which can activate calcium-mediated signaling pathways affecting proteins like LRRC16B. | ||||||